Orient Pharma Co (ROCO:4166) LT-Debt-to-Total-Asset: 0.06 (As of Dec. 2025)

What is Orient Pharma Co LT-Debt-to-Total-Asset?

Orient Pharma Co ROCO:4166 +0.18% 61 LT-Debt-to-Total-Asset is 0.06 as of Dec. 2025. GuruFocus rates ROCO:4166 with a GF Score™ of 61/100 and a GF Value™ of NT$45.13 (Significantly Undervalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orient Pharma Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.06.

Orient Pharma Co's long-term debt to total assets ratio declined from Dec. 2024 (0.09) to Dec. 2025 (0.06). It may suggest that Orient Pharma Co is progressively becoming less dependent on debt to grow their business.

Orient Pharma Co (ROCO:4166) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orient Pharma Co LT-Debt-to-Total-Asset Related Terms

Orient Pharma Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co LT-Debt-to-Total-Asset Chart

Orient Pharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.22

0.13

0.09

0.06

Orient Pharma Co Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.09	0.08	0.06	0.06

61GF Score

Orient Pharma Co Ltd ROCO:4166

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Orient Pharma Co LT-Debt-to-Total-Asset Calculation

Orient Pharma Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	179.813	/	2938.353
	=	0.06

Orient Pharma Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	179.813	/	2938.353
	=	0.06

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.06 mean?

Orient Pharma Co (ROCO:4166) has a LT-Debt-to-Total-Asset of 0.06 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orient Pharma Co and its competitors.

Is Orient Pharma Co's LT-Debt-to-Total-Asset too high?

Orient Pharma Co's current LT-Debt-to-Total-Asset is 0.06. Overall, Orient Pharma Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Orient Pharma Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Orient Pharma Co's LT-Debt-to-Total-Asset of 0.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current LT-Debt-to-Total-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Orient Pharma Co stock overvalued right now?

Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.13, compared to a current price of NT$27.25 — trading 39.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.06. Orient Pharma Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current LT-Debt-to-Total-Asset is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.25 is trading 39.6% below its estimated GF Value™ of NT$45.13. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

LT-Debt-to-Total-Asset: 0.06
GF Value™: NT$45.13 vs. price of NT$27.25 (39.6% below fair value)
GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TPE:4746 ROCO:6467 TPE:4119 TPE:3054 ROCO:6785 ROCO:7829 ROCO:4120 ROCO:1799 ROCO:4127 TPE:1731 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106

Website https://www.oppharma.com

Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.

61GF Score

Get the complete analysis for ROCO:4166

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.25

Price

NT$45.13

GF Value

View ROCO:4166 Analysis

See LT-Debt-to-Total-Asset data for all stocks →